@inproceedings{inproceedings, title  = {{1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2014}},

 month = {{5}},

 author = {{Parker C and Vogelzang NJ and Sartor AO and Bottomley D and Coleman RE and Skjorestad I and Wahba M and Nilsson S}},

 doi = {{10.1200/jco.2014.32.15_suppl.5070}},

 volume = {{32}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{5070-5070}},

 note = {{Accessed on 2025/10/10}}}